Novakutan-BTA

2023: Product Announcement

In early December 2023, it became known that sales of Novakutan-BTA, an analogue of Botox produced by the South Korean company Huons Global, began in Russia. The substance is intended for use in cosmetology in order to smooth facial lines.

The holder of the marketing authorization for Novakutan-BTA is Fizhi Beauty Institute LLC, which is responsible for the quality and safety of the drug. The structures of this organization were previously supplied to the Russian Federation by Aquashine fillers and revitalizers of South Korean Caregen. The rights to the Novakutan-BTA trademark belong to the Medbisistem company, the founder of which is Yulia Mironova, the founder of the Fizhi Beauty Institute.

Sales of Novakutan-BTA have begun

According to the Kommersant newspaper, the first batch of botulinum toxin Novakutan-BTA was put into circulation in Russia by Figi SM, the owner of which, as of December 2023, is Larisa Orlovskaya, the ex-general director of the charity fund of the United Metallurgical Company OMK-Participation. It is noted that Novakutan-BTA is approved in a number of other countries: Huons Global supplies it under the Hutox brand to Ecuador, the Dominican Republic, Iraq, Bolivia, Georgia and some CIS states.

After the withdrawal of the Botox drug from the Russian market of the American company Allergan, due to geopolitical tensions, the released niche began to be shared by other players. Alternative agents include the Russian drugs Miotox and Relatox, as well as Dysport and Xeomin, produced by the French Ipsen and German Merz, respectively. With such competition, Nikolai Bespalov, Development Director of RNC Pharma, believes that it will be difficult for Novakutan-BTA to take a significant market share: according to him, "it is unlikely to exceed 5-10%."^[1]

Notes